Fireside Chat, Interview
Pande & Conde: When (and How) Biology Becomes Engineering
- Core Paradigm Shift: The bioindustry is transitioning from stochastic, hypothesis-driven science to methodical, design-driven engineering, moving from "discovering parts" to "building systems."
- Modular "Lego" Approach: Biology is treated as a hierarchical stack (atoms to ecosystems) where standardized, interchangeable biological parts can be mixed and matched, analogous to mechanical components.
- Example: CAR-T therapy utilizes distinct engineered components, while companies like Asimov are explicitly developing the biological "Legos" to facilitate this assembly.
- Disciplinary Convergence: Traditional engineering fields (mechanical, electrical, materials, computer science) are applying universal design principles to biological substrates (bone, muscle) rather than steel.
- Academic Evolution: The creation of dedicated bioengineering departments in the last decade has accelerated the flow of cross-disciplinary talent, allowing engineers to enter biology and biologists to adopt engineering mindsets.
- Genetic Engineering Maturation: CRISPR and synthetic biology platforms have shifted genetic engineering from stochastic "playing Boggle" (random mutation screening) to DNA as a true design medium.
- Machine Learning Integration: ML serves as a critical engineering bridge, transforming bespoke, decades-long discovery cycles into reproducible, data-driven processes where false positives provide equal learning value to true positives.
- Value Model Reversal: Under engineering principles, the value of drug assets increases chronologically (Asset #2 > Asset #1) because each iteration improves the platform's predictive power and efficiency.
- Industry Behavior Change: Pharmaceutical companies are shifting from viewing themselves solely as asset developers to becoming data-generating entities, anticipating a future where "dry labs" (computational) rival the size of "wet labs."
- New Job Roles: The role of the medicinal chemist is evolving into "drug designer/engineer," focusing on synthesis planning and design while outsourcing actual synthesis to CROs.
- Platform Valuation Shift: Market dynamics are moving from valuing single high-potential assets to valuing reproducible platforms capable of systematically generating multiple successful assets.
- Proof of Concept Strategy: Success in business development now requires demonstrating high predictability and reproducibility (e.g., a high success rate for designed functions) rather than stochastic success ratios (e.g., 1 in 10,000).
- "Land and Expand" Application: Unlike traditional biotech where expansion was difficult due to bespoke processes, engineering approaches allow for scalable, iterative improvement across different biological contexts.
- Compounding Innovation: The industry is adopting a growth model similar to Illumina's sequencing trajectory, where incremental improvements (e.g., 30% better annually) compound to make previously impossible outcomes achievable.
- Strategic Roadmapping: Large-scale goals (e.g., increasing human longevity) are being deconstructed into modular, engineering-based milestones (like the Mercury-Gemini-Apollo sequence) to manage risk and validate feasibility step-by-step.